glp·helper
glphelper.com/tirzepatide/north-carolina/cornelius
Dual GIP / GLP-1 receptor agonistFDA-approved May 2022 (Mounjaro) · November 2023 (Zepbound)Rx · Subcutaneous injection · Once weekly

Tirzepatide® providers &
prescriptions in Cornelius, NC

Verified Tirzepatide providers in Cornelius, NC. Checked against the NPI registry, never ranked by who pays us.[7]

city providers
22
as of today
§ 02Provider directory: North Carolina
22 of 22 shown

Find a Tirzepatide provider in North Carolina.

Every entry is checked against the federal NPI registry. We do not accept payment for placement.

Filter →
Type
Provider
City
Insurance / phone
Browse by North Carolina city · /tirzepatide/north-carolina/{city}
§ 03Getting Tirzepatide in Cornelius
22 providers · Cornelius, NC

How to get Tirzepatide in Cornelius.

22 GLP-1 prescribers and 6 local resource types are on record for Cornelius, plus 3 nearby towns in the directory.

Prescribers in Cornelius
22 prescribers
22 GLP-1 prescribers in Cornelius, most listed as Family Medicine (14), Internal Medicine (7) and Internal Medicine, Endocrinology, Diabetes & Metabolism (1). Any North Carolina-licensed physician, nurse practitioner, or PA can prescribe Tirzepatide, over video or in person. The nearest towns on record are Huntersville (31 providers), Mooresville (22 providers) and Concord (30 providers).
Around the prescription in Cornelius
6 listed nearby
19 dietitians, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 6 places to move are on record near Cornelius.
Medicaid (weight loss)
Covered
As of April 2026, North Carolina Medicaid covers GLP-1s for weight loss, usually with prior authorization and BMI criteria, on top of the standard diabetes coverage. Employer and private plans vary; coverage is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm North Carolina’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

The molecule in Mounjaro and Zepbound. It acts on two gut-hormone pathways, GIP and GLP-1.

Tirzepatide is a once-weekly injection sold by Eli Lilly as Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management). It is the first approved dual GIP/GLP-1 receptor agonist. It activates two gut-hormone pathways rather than one, which is associated with greater average weight loss than single GLP-1 agonists.[2][3]

In SURMOUNT-1, adults with obesity (without diabetes) lost a mean of 20.9% of body weight on the 15 mg dose at 72 weeks, versus 3.1% on placebo. In the SURPASS-2 head-to-head diabetes trial, tirzepatide produced larger HbA1c and weight reductions than semaglutide 1 mg.[1]

At a glanceMultiple (brand-specific)
Generic name
tirzepatide
Drug class
Dual GIP / GLP-1 receptor agonist
Manufacturer
Eli Lilly
FDA approved
May 2022 (Mounjaro) · November 2023 (Zepbound)
Approved use
Type 2 diabetes (Mounjaro) · chronic weight management (Zepbound)
Off-label use
Use outside the approved brand/indication is off-label
Administration
Subcutaneous injection · Once weekly
Available doses
2.5 mg · 5 mg · 7.5 mg · 10 mg · 12.5 mg · 15 mg
Half-life
≈ 5 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy; may reduce oral contraceptive efficacy

Community health · CDC

Weight & metabolic health in Cornelius

Cornelius, North Carolina has a population of 31,412 people. The adult obesity rate in Cornelius is an age-adjusted estimate of 25.1%, 9.4 percentage points below the North Carolina state rate of 34.5%. Diagnosed diabetes reaches 7.1% of adults in Cornelius. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 15.3% of adults in Cornelius.

of Cornelius adults have obesity
25.1%
diagnosed diabetes
7.1%
no regular physical activity
15.3%

Age-adjusted estimates for Cornelius, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight lossthe science of Ozempic face
§ 05Support around Tirzepatide in Cornelius
6 fitness clubs

The prescription is one part. Here is the rest, in Cornelius.

Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near Cornelius, NC, ordered as the registry lists them, never by who pays us.

Fitness clubs and recreation centers

Fitness clubs and recreation centers run classes and pools, an easier start than a weight room.

Northern Regional Recreation Center
REC CENTER
4.5 on Google · 365 reviews
18121 Old Statesville Rd
Website
Xtreme Fitness Center
FITNESS
4.9 on Google · 17 reviews
18335 Old Statesville Rd
M&M Fitness LKN
FITNESS
5.0 on Google · 12 reviews
140 Jackson St. Davidson
TruForge Fitness
FITNESS
5.0 on Google · 6 reviews
10616 Bailey Rd Ste I
Website
Planet Fitness
GYM
4.5 on Google · 749 reviews
19706 One Norman Blvd A
Website
Gold's Gym Lake Norman
GYM
3.8 on Google · 272 reviews
20420 W Catawba Ave
Website

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Anjana Agarwal, MS RD LDN CNSD
RD
Registered dietitian
16501 D Northcross Drive
Call 704-895-9865NPI 1356415715
Amanda Averett, MS, RDN, LDN
RD
Registered dietitian
19607 W Catawba Ave Ste 102
Call 919-603-7631NPI 1720630585
Kylie Boyer, RDN
RD
Registered dietitian
19408 Carrington Club Dr
Call 717-982-5959NPI 1154266948
Holly Brewer, RD
RD
Registered dietitian
101 E Wt Harris Blvd Ste 2122B
Call 704-863-5713NPI 1407306889
Susan Crosby, RD, LDN
RD
Registered dietitian
16501 Northcross Dr
Call 704-895-9865NPI 1225247166
Cindy Custer, RD
RD
Registered dietitian
18137 W Catawba Ave
Call 949-294-8834NPI 1760974026
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the SURMOUNT weight-management program and the SURPASS diabetes program, including the SURPASS-2 head-to-head against semaglutide. Figures are means at each trial's primary endpoint.

SURMOUNT-1 randomized 2,539 adults with obesity (without diabetes) across 72 weeks. Mean weight change was −15.0% (5 mg), −19.5% (10 mg), and −20.9% (15 mg) versus −3.1% with placebo. A majority of patients on the higher doses lost ≥20% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (15 mg)
−20.9%
SURMOUNT-1, 72 wk vs −3.1% placebo[2]
Mean weight change (5 mg)
−15.0%
SURMOUNT-1, 72 wk[2]
HbA1c reduction (T2D)
−1.8 to −2.6%
SURPASS program[4]
vs. semaglutide 1 mg
Superior
SURPASS-2, HbA1c + weight[3]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average tirzepatide weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
12 to 24%
mild
Dose-dependent; usually eases after titration
Diarrhea
12 to 19%
mild
More frequent during dose escalation
Vomiting
5 to 13%
mild
Reduced by slower titration
Constipation
6 to 17%
mild
Decreased appetite
5 to 11%
mild
Expected pharmacologic effect
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
~1 to 2%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash, Zepbound (no insurance)
$1,000 to $1,300
per month
Brand-name retail; Lilly self-pay vials lower for some doses[6]
Cash, Mounjaro (no insurance)
$1,000 to $1,200
per month
Brand-name retail average[6]
Commercial insurance (T2D)
$25 to $250
per month copay
Usually covered for diabetes with prior authorization
Commercial insurance (weight)
Often denied
Zepbound is on-label but frequently requires PA
Medicare Part D
$0 to $100
per month
T2D covered; weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $25
per month
Commercial insurance only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Tirzepatide providers in North Carolina

NPI-verified Tirzepatide (tirzepatide) prescribers and clinics, never ranked by who pays us.

Tirzepatide in other states

Find NPI-verified Tirzepatide (tirzepatide) doctors, clinics, and pharmacies in the states we cover, never ranked by who pays us.

Related GLP-1 research
§ 09Frequently asked: Tirzepatide in North Carolina

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Tirzepatide is the active molecule in both Eli Lilly products. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. They are the same drug with different approved indications, and insurers treat them as separate products.[1]